Figure 2.

Clinical pathway of sunitinib treatment. d, in patients with a RECIST assessment of “PD”, the treatment may be selected after the efficacy is confirmed by the researcher (e.g., combined with Choi assessment); e, dosage should be adjusted according to toxicity grade, and the minimal dose should not be lower than sunitinib 12.5 mg qd; f, for instance, the initial 4/2 protocol can be adjusted to 2/1 protocol; g, please refer to the information described in the main text concerning the third-line treatment. TKI, tyrosine kinase inhibitor.